Sequence Review: Is This GLP-1 Program Worth It?
A detailed review of Sequence's GLP-1 weight loss program, covering their premium positioning, obesity medicine specialists, pricing, insurance acceptance, and how Sequence compares to more affordable options like Trimi.
More on GLP-1 Provider Comparisons
Sequence: Premium Positioning in the GLP-1 Market
Sequence has carved out a distinct position in the crowded telehealth weight loss market by focusing on clinical premium — specifically, by staffing its platform with board-certified obesity medicine specialists and building its business model around helping patients access brand-name GLP-1 medications through insurance coverage. This approach sets Sequence apart from the many platforms that have emerged primarily around compounded GLP-1 access.
The company's core thesis is that the quality of the prescribing physician matters as much as the medication itself, and that patients benefit from working with clinicians who have specific, certified expertise in obesity as a medical condition. Board-certified obesity medicine physicians complete additional fellowship training or continuing education focused on the pathophysiology of obesity, the pharmacology of weight loss medications, the metabolic consequences of excess weight, and the evidence-based strategies for long-term weight management.
In practice, this means that Sequence consultations tend to be more clinically intensive than what patients experience on general telehealth platforms. Providers may discuss metabolic testing, evaluate for secondary causes of weight gain (such as thyroid disorders, Cushing syndrome, or medication-induced weight gain), and create more detailed treatment plans that account for comorbidities like type 2 diabetes, obstructive sleep apnea, or polycystic ovary syndrome. For patients with complex medical histories, this depth of clinical evaluation is genuinely valuable.
The question, however, is whether the premium positioning justifies the premium price for every patient — particularly those with straightforward clinical profiles who primarily need affordable access to effective semaglutide or tirzepatide therapy.
Sequence Pricing: The Full Cost Picture
Understanding Sequence's total cost requires separating the membership fee from the medication cost, because unlike many compounded GLP-1 platforms that bundle everything into one price, Sequence charges these separately. This structure makes sense given their insurance-focused model but creates a more complex cost calculation for patients.
The Sequence membership fee has generally been in the range of $99 to $199 per month. This covers access to your obesity medicine specialist, ongoing clinical monitoring, messaging with your care team, and the platform's insurance navigation services. The membership itself does not include medication — it is purely for the clinical relationship and platform access.
Medication costs on top of the membership depend entirely on the insurance pathway. For patients whose insurance covers brand-name GLP-1 medications, the additional medication cost may be a manageable copay — sometimes as low as $25 to $100 per month depending on the plan. In this best-case scenario, a Sequence patient might pay approximately $125 to $300 total per month for specialist care plus insured medication, which can actually be competitive with or even less expensive than some compounded GLP-1 platforms. Sequence genuinely shines in this scenario.
The problem is that this best-case scenario does not apply to most patients. Many insurance plans do not cover GLP-1 medications for weight loss, cover them only with significant restrictions and prior authorization requirements, or deny coverage outright. For patients without adequate insurance coverage, the math changes dramatically: a $99 to $199 membership fee plus $1,000 or more per month for brand-name medication makes Sequence one of the most expensive pathways to GLP-1 therapy available. In these cases, a platform like Trimi offering affordable compounded GLP-1 medications with all-inclusive pricing provides dramatically better value.
Insurance Reality Check
Before committing to an insurance-dependent platform like Sequence, verify your specific plan's coverage for GLP-1 weight loss medications. Many plans exclude these medications entirely, cover them only for type 2 diabetes, or require extensive prior authorization documentation. A coverage denial after starting the program can be both frustrating and costly. For a full breakdown of medication costs, see our semaglutide cost guide.
The Insurance Navigation Advantage
Where Sequence provides clear, tangible value is in its insurance navigation capabilities. For patients with insurance plans that cover GLP-1 medications, the process of actually obtaining coverage is often labyrinthine — requiring specific documentation, diagnostic coding, prior authorization submissions, and sometimes appeals of initial denials. Sequence has built expertise in this process that most patients and even many general practitioners lack.
Sequence's team handles the prior authorization process, prepares the clinical documentation that insurance companies require, and can submit appeals when initial requests are denied. This administrative heavy lifting is genuinely time-consuming and requires specific knowledge of how insurance companies evaluate GLP-1 coverage requests. For patients who have tried to navigate this process on their own and hit dead ends, Sequence's expertise can be the difference between coverage approval and denial.
The honest assessment is that if you have strong insurance coverage for GLP-1 medications, Sequence's insurance navigation service is valuable and can pay for itself many times over. Getting a $1,300-per-month brand-name medication covered at a $50 copay easily justifies a $149 monthly membership fee. However, if your insurance does not cover these medications — and many plans still do not — Sequence's insurance expertise becomes irrelevant, and you are left paying a premium membership fee without the primary benefit it was designed to deliver.
This is why understanding your insurance coverage before choosing a platform is so important. Patients with confirmed GLP-1 coverage should seriously consider Sequence. Patients without coverage, or with uncertain coverage, may want to start with a more affordable platform like Trimi and explore insurance options in parallel rather than committing to a premium membership that depends on insurance approval.
Brand-Name Only: A Strength and a Limitation
Sequence's historical focus on brand-name GLP-1 medications is both its defining characteristic and its primary limitation. On one hand, brand-name medications like Wegovy and Zepbound are FDA-approved products with extensive clinical trial data, standardized manufacturing, and prefilled injection pens that simplify dosing. The clinical certainty that comes with brand-name products is real and meaningful.
On the other hand, the brand-name-only approach means that Sequence patients are fully dependent on insurance coverage for affordability, subject to the ongoing supply shortages that have plagued brand-name GLP-1 medications, and unable to access the significantly lower-cost compounded alternatives that have become the primary pathway for most out-of-pocket patients. When brand-name supply is constrained, Sequence patients may face treatment interruptions that compounded-medication patients avoid.
Platforms like Trimi that work with licensed 503B compounding pharmacies offer a different value proposition: affordable access to the same active ingredients without the supply chain vulnerabilities that affect brand-name products. Compounded semaglutide and tirzepatide undergo potency and sterility testing, are produced by regulated facilities, and are available at prices that make long-term GLP-1 therapy financially sustainable for patients paying out of pocket. For a thorough analysis of compounded medication quality standards, see our guide on compounded semaglutide safety in 2026.
Pros and Cons of Sequence
Sequence: Strengths
Board-certified obesity medicine specialists provide deep clinical expertise in weight management
Excellent insurance navigation that can secure coverage for brand-name GLP-1 medications
Access to FDA-approved brand-name products with standardized, prefilled dosing formats
Thorough clinical evaluations that assess for secondary causes of weight gain and comorbidities
Strong fit for patients with complex medical histories requiring specialized obesity management
Sequence: Limitations
Monthly membership fee is charged on top of medication costs, increasing total expense
Without insurance coverage, total costs can exceed $1,200 per month for membership plus medication
Historical focus on brand-name medications limits access to affordable compounded alternatives
Insurance approval process can take weeks, delaying treatment initiation
Vulnerable to brand-name supply shortages that have affected Wegovy, Ozempic, and Zepbound availability
Premium pricing model is difficult to justify for patients with straightforward clinical profiles
Sequence vs. Trimi: A Clear Comparison
The comparison between Sequence and Trimi highlights the different philosophies in the GLP-1 telehealth space: premium specialist care with insurance navigation versus focused, affordable direct access to compounded medications with specialized providers.
Choose Sequence if: You have insurance that covers GLP-1 medications and want help navigating coverage. You have complex medical comorbidities and want an obesity medicine specialist managing your care. You prefer brand-name medications and are willing to pay a membership premium for that access. You value the specific credential of board-certified obesity medicine over other provider qualifications.
Choose Trimi if: You are paying out of pocket and want the most affordable path to effective GLP-1 therapy. You want transparent, all-inclusive pricing without separate membership and medication fees. You want access to both compounded semaglutide and tirzepatide with flexibility to switch between them. You want fast turnaround from assessment to medication delivery without waiting for insurance approvals. You want board-certified providers who specialize in GLP-1 therapy at a price point that is sustainable for long-term treatment.
For the majority of patients currently seeking GLP-1 therapy — those paying out of pocket because insurance either does not cover these medications or makes coverage exceedingly difficult to obtain — Trimi's model typically delivers better value. For the subset of patients with strong insurance coverage who want specialist-level care, Sequence's approach has clear merit. Both platforms operate with licensed providers and genuine medications — the difference is in the model and cost structure, not in the fundamental legitimacy of the care. Learn more about how to get GLP-1 prescribed online through various platforms.
Frequently Asked Questions
What is Sequence weight loss?
Sequence is a premium telehealth weight loss platform that focuses specifically on GLP-1 medications prescribed by board-certified obesity medicine specialists. Unlike general telehealth platforms, Sequence positions itself at the higher end of the market with an emphasis on clinical expertise and insurance-facilitated access to brand-name GLP-1 medications. The platform pairs patients with physicians who hold board certification in obesity medicine, which is a specialized credential beyond general medical licensing.
How much does Sequence cost?
Sequence charges a monthly membership fee that has generally been in the range of $99 to $199 per month. This membership covers provider consultations, clinical monitoring, and platform access, but it does not include the cost of medication. Medication costs are separate and depend on whether you obtain brand-name GLP-1 medications through insurance (which Sequence helps facilitate) or pay out of pocket. With insurance, patients may pay copays ranging from $25 to $100 per month for brand-name medications. Without insurance, brand-name GLP-1 medications can exceed $1,000 per month on top of the Sequence membership fee.
Does Sequence accept insurance?
Sequence's primary strategy has been to help patients access brand-name GLP-1 medications through their insurance coverage. The platform assists with insurance verification, prior authorization submissions, and appeals when claims are denied. This insurance-focused approach can result in significantly lower medication costs for patients with plans that cover obesity medications. However, not all insurance plans cover GLP-1 medications for weight loss, and even those that do often require prior authorization, step therapy, or other utilization management hurdles that can delay treatment initiation.
Does Sequence offer compounded semaglutide?
Sequence has historically focused on brand-name GLP-1 medications rather than compounded formulations. Their model is built around insurance-facilitated access to FDA-approved products like Wegovy, Ozempic, Mounjaro, and Zepbound. However, the telehealth landscape evolves rapidly, and Sequence may have adjusted its offerings in response to market conditions and patient demand. Patients who specifically want affordable compounded GLP-1 medications may find platforms like Trimi, which are built around compounded formulations, to be a more direct and cost-effective path.
Are Sequence's obesity medicine specialists better than regular doctors?
Board-certified obesity medicine specialists have completed additional training and certification specifically in the medical management of obesity. This specialized credential, offered through the American Board of Obesity Medicine, requires dedicated study and examination beyond standard medical training. These specialists may have deeper knowledge of weight loss pharmacology, metabolic physiology, and the clinical nuances of long-term weight management. However, many excellent GLP-1 prescribers are not board-certified in obesity medicine specifically — board-certified providers in internal medicine, family medicine, and endocrinology also prescribe GLP-1 medications effectively. The credential is meaningful but not the only indicator of prescribing quality.
Can I switch from Sequence to Trimi?
Yes, switching from Sequence to Trimi is a straightforward process. Complete Trimi's online health assessment, provide your current medication and dosage information, and a Trimi provider will review your history to ensure continuity of care. Many patients switch from Sequence when they want more affordable GLP-1 access without the premium membership fees, or when their insurance does not adequately cover brand-name medications. Plan the transition to ensure no gap in your medication supply.
Is Sequence worth the higher price?
Sequence's value proposition depends heavily on your insurance situation. If your insurance covers brand-name GLP-1 medications and you want a platform that specializes in navigating that coverage, Sequence's membership fee plus covered medication copays may actually result in competitive total costs. However, for patients without insurance coverage for GLP-1 medications — which represents a large portion of the market — Sequence's premium membership fee on top of out-of-pocket brand-name medication costs makes it one of the most expensive options available. In that scenario, a focused platform like Trimi offering affordable compounded medications typically provides far better value.
Sources & References
- Sequence Health. Official Website and Program Information. 2026.
- American Board of Obesity Medicine. "About ABOM Certification." 2025.
- Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." NEJM, 2021;384:989-1002.
- Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity." NEJM, 2022;387:205-216.
- Novo Nordisk. Wegovy (semaglutide) Prescribing Information. 2024.
- Eli Lilly. Zepbound (tirzepatide) Prescribing Information. 2024.
- Obesity Medicine Association. "Insurance Coverage for Obesity Treatment." Position Statement, 2025.
- FDA. "Compounding and the FDA: Questions and Answers." U.S. Food and Drug Administration, 2025.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program. Pricing and availability information is approximate and subject to change. Insurance coverage varies by plan and is not guaranteed. This article was prepared by the Trimi Medical Team and naturally reflects our perspective, though we have made every effort to present competitor information fairly and accurately.